PDGFR alpha antibody and other kinase pathway antibodies: buy the pair, read the ratio

Running a pathway experiment

1. Buy the pair and read the ratio. Phospho signal is read against total protein on the same samples, because the informative quantity is the fraction activated. Normalising a phospho band to a loading control alone cannot separate more activation from more kinase.
2. Put phosphatase inhibitors in before you lyse. Dephosphorylation begins the moment a cell breaks. Inhibitors go into the buffer fresh, the plate goes on ice and the lysate is handled cold and fast. Most missing phospho signal is lost in the first minute and no optimisation recovers it.
3. Use a selective inhibitor as the specificity control. A band that disappears when the kinase is inhibited is the kinase's band. This is the strongest and cheapest specificity evidence available for a phospho reagent and it is routinely skipped in favour of an isotype control that proves much less.
4. Check the residue and its conservation. Phospho antibodies are residue specific and different sites report different downstream consequences. Put the residue in the methods, and confirm the surrounding sequence is conserved in your species before assuming cross-reactivity.
5. Remember that some of these move rather than change. A transcriptional co-activator is regulated by shuttling between cytoplasm and nucleus, so a whole-cell blot can be flat while the biology changes entirely. For those targets, fractionate or measure a per-cell nuclear ratio by imaging.

Time courses, because pathways are transient

Receptor and downstream phosphorylation peak within minutes and decay, so a single time point sits somewhere on a curve you have not measured. A short course is what makes a comparison between conditions mean anything.

When comparing cell lines, the kinetics themselves usually differ, so matching one time point across lines compares the timing rather than the magnitude of the response.

Alternatives to the blot

Immunoassay formats quantify phosphorylation across many samples reproducibly, and cytometry measures it per cell, which reveals whether a population responds uniformly or a subset responds strongly. Both answer questions a blot averages away.

For a screen, a plate-based phospho immunoassay is far more practical than a blot per condition and is what makes a dose response across many compounds feasible.

A RACK1 antibody reports a scaffold, not a switch

Scaffold proteins organise a pathway without catalysing anything, so their abundance rarely changes when the pathway turns on. That makes them poor readouts of activity and, for the same reason, tempting loading controls, which is how they end up in blots for two incompatible purposes.

If a scaffold is being used as a loading control, it has to be inside its linear range and shown not to change under the treatment. If it is the subject of the experiment, the question is usually where it is and what it is bound to, which is an immunoprecipitation or an imaging question rather than a blot one.

A raptor antibody and a complex component

Raptor defines one of the two mTOR complexes, so a raptor antibody is how that complex is identified and immunoprecipitated, while the pathway's activity is read downstream as S6 kinase and 4E-BP1 phosphorylation. Its own level is stable. Complex integrity depends on the lysis buffer, since detergent choice can dissociate it, and that belongs in the method.

A smad2 antibody and a signal read as location

SMAD2 moves to the nucleus when it is phosphorylated at its carboxy terminus, so a smad2 antibody for total protein is read with a phospho clone and with a fractionation or an image, because translocation is the signal. The response peaks within an hour and adapts, so a single late sample can look like no signal. SMAD3 is close enough that cross reactivity data matter.

A phospho stat3 antibody and the residue it names

Phosphorylation at tyrosine 705 drives dimerisation and nuclear entry while a serine site modulates transcription, so a phospho stat3 antibody has to name its residue and the figure has to say which was measured, with total STAT3 on the same membrane. Phosphatase inhibitors go into the buffer before the cells are scraped, and a cytokine stimulated positive control belongs on the gel.

An s6k1 antibody and the substrate that reports a pathway

S6 kinase 1 is the classic readout of mTOR complex 1, so an s6k1 antibody is bought with a phospho clone against the threonine in its hydrophobic motif, and the ratio is the measurement. Two isoforms of different mass arise from alternative starts. Rapamycin treatment is the control that should collapse the phospho signal while leaving the total protein where it was.

Common questions

Why is my phospho mTOR antibody band missing?

Handling, almost always. Phosphatase inhibitors must be in the lysis buffer before lysis, and everything kept cold and fast. A stimulated positive control tells you in one lane whether it is handling or biology.

What is the best specificity control for a phospho antibody?

A selective inhibitor of the kinase. A band that disappears under inhibition is the kinase's band, which is far stronger evidence than an isotype control and usually cheaper than a genetic approach.

Should phospho be normalised to total or to a loading control?

To total on the same samples. The meaningful quantity is the fraction of the protein that is phosphorylated, and a loading control alone conflates activation with abundance.

Why is my YAP1 antibody blot flat when the treatment clearly works?

Because it is regulated by moving rather than by amount. Fractionate into nuclear and cytoplasmic pools, or image and measure a nuclear to cytoplasmic ratio per cell.

Is a scaffold protein a safe loading control?

Only after you have shown it does not change under your treatment and that it is loaded inside the linear range. Total protein staining measures what was loaded and avoids the assumption altogether.

Browse by service class

• Compare Gene synthesis on advertised prices